Advanced Accelerator Applications是一家放射性药物研发商,公司开发了一种用于肿瘤适应症的治疗配对管道,主要产品包括正电子发射断层扫描和单光子发射计算机断层扫描的分子核诊断放射性药物等,集中应用于临床肿瘤学、心脏病学、神经病学和感染性、炎症性疾病的诊断领域。近日,西门子医疗宣布,已完成对诺华旗下Advanced Acceler...
Advanced Accelerator Applications是一家放射性药物研发商,公司开发了一种用于肿瘤适应症的治疗配对管道,主要产品包括正电子发射断层扫描和单光子发射计算机断层扫描的分子核诊断放射性药物等,集中应用于临床肿瘤学、心脏病学、神经病学和感染性、炎症性疾病的诊断领域。近日,西门子医疗宣布,已完成对诺华旗下Advanced Acceler...
5家值得关注的核药公司 诺华在2017年以39亿美元收购Advanced AcceleratorApplications(AAA),获得了Lutathera;在2018年以21亿美元收购Endocyte,获得了Pluvicto。 Lutathera在2018年获批上市,2023年销售额超6亿美元,2024年上半年以两位数增速增长至3.44亿美元;Pluvicto在2022年上市,2023年销售额达到9.8亿美元,2024上半年以4...
At Advanced Accelerator Applications, we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision diagnostic solutions for oncology.
By accessing and browsing this Site, you accept, without limitation or qualification, these Terms and Conditions and acknowledge that any other agreements regarding the use of this Site between you and Advanced Accelerator Applications SA are superseded and of no force or effect. 2. Use of ...
天眼查为您提供Advanced Accelerator Applications公司概况:Advanced Accelerator Applications,成立于2002-01-01,位于法国,融资轮次IPO上市。查公司,查老板,查关系就上天眼查。
At Advanced Accelerator Applications, we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision diagnostic solutions for oncology.
12月10日, 西门子 医疗宣布,已完成对诺华旗下子公司 Advanced Accelerator Applications(以下简称:AAA)分子成像业务的收购,诺华AAA分子成像业务位于欧洲,生产并销售用于正电子发射断层扫描(PET)的放射性药物。收购完成后,AAA将成为 西门子 医疗旗下的一家公司。此
Advanced Accelerator Applications SA ADR(AAAP)股吧,股民朋友可以在这里畅所欲言,分析讨论股票名的最新动态。东方财富股吧,专业的股票论坛社区。
Our research tasks span the range of technology areas for transmutation, gas-cooled reactor technology, and high temperature heat exchangers, including separation of actinides from spent nuclear fuel, methods of fuel fabrication, reactor-accelerator coupled experiments, corrosion of materials exposed to ...